This study investigates metastatic pancreatic ductal adenocarcinoma. Participants will receive chemotherapy with or without an investigational medication.
The study evaluates the safety and effectiveness of the treatment options. It looks at how well participants tolerate the treatments.
- Who can participate: Adults with metastatic pancreatic ductal adenocarcinoma and a KRAS G12D mutation may join. Participants should not have had prior systemic treatment for their cancer and must have good organ function.
- Study details: Participants will receive chemotherapy and may receive an investigational medication. Some participants may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.